Literature DB >> 25746197

Development and initial validation of a brief self-report measure of cognitive dysfunction in fibromyalgia.

Anna L Kratz1, Stephen G Schilling2, Jenna Goesling3, David A Williams4.   

Abstract

UNLABELLED: Pain is often the focus of research and clinical care in fibromyalgia (FM); however, cognitive dysfunction is also a common, distressing, and disabling symptom in FM. Current efforts to address this problem are limited by the lack of a comprehensive, valid measure of subjective cognitive dysfunction in FM that is easily interpretable, accessible, and brief. The purpose of this study was to leverage cognitive functioning item banks that were developed as part of the Patient Reported Outcomes Measurement Information System (PROMIS) to devise a 10-item short form measure of cognitive functioning for use in FM. In study 1, a nationwide (U.S.) sample of 1,035 adults with FM (age range = 18-82, 95.2% female) completed 2 cognitive item pools. Factor analyses and item response theory analyses were used to identify dimensionality and optimally performing items. A recommended 10-item measure, called the Multidimensional Inventory of Subjective Cognitive Impairment (MISCI) was created. In study 2, 232 adults with FM completed the MISCI and a legacy measure of cognitive functioning that is used in FM clinical trials, the Multiple Ability Self-Report Questionnaire (MASQ). The MISCI showed excellent internal reliability, low ceiling/floor effects, and good convergent validity with the MASQ (r = -.82). PERSPECTIVE: This paper presents the MISCI, a 10-item measure of cognitive dysfunction in FM, developed through classical test theory and item response theory. This brief but comprehensive measure shows evidence of excellent construct validity through large correlations with a lengthy legacy measure of cognitive functioning.
Copyright © 2015 American Pain Society. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Fibromyalgia; Multidimensional Inventory of Subjective Cognitive Impairment (MISCI); Patient Reported Outcomes Measurement Information System (PROMIS); cognitive functioning; self-report

Mesh:

Year:  2015        PMID: 25746197      PMCID: PMC4456217          DOI: 10.1016/j.jpain.2015.02.008

Source DB:  PubMed          Journal:  J Pain        ISSN: 1526-5900            Impact factor:   5.820


  33 in total

1.  Development of the Mental Clutter Scale.

Authors:  Frank Leavitt; Robert S Katz
Journal:  Psychol Rep       Date:  2011-10

2.  Distraction as a key determinant of impaired memory in patients with fibromyalgia.

Authors:  Frank Leavitt; Robert S Katz
Journal:  J Rheumatol       Date:  2006-01       Impact factor: 4.666

3.  Concentration and memory deficits in patients with fibromyalgia syndrome.

Authors:  G M Grace; W R Nielson; M Hopkins; M A Berg
Journal:  J Clin Exp Neuropsychol       Date:  1999-08       Impact factor: 2.475

4.  The use of PROMIS and assessment center to deliver patient-reported outcome measures in clinical research.

Authors:  Richard C Gershon; Nan Rothrock; Rachel Hanrahan; Michael Bass; David Cella
Journal:  J Appl Meas       Date:  2010

5.  Efficacy and safety of milnacipran 100 mg/day in patients with fibromyalgia: results of a randomized, double-blind, placebo-controlled trial.

Authors:  Lesley M Arnold; R Michael Gendreau; Robert H Palmer; Judy F Gendreau; Yong Wang
Journal:  Arthritis Rheum       Date:  2010-09

6.  Identifying the clinical domains of fibromyalgia: contributions from clinician and patient Delphi exercises.

Authors:  Phillip J Mease; Lesley M Arnold; Leslie J Crofford; David A Williams; I Jon Russell; Louise Humphrey; Linda Abetz; Susan A Martin
Journal:  Arthritis Rheum       Date:  2008-07-15

7.  Exercise in warm water decreases pain and improves cognitive function in middle-aged women with fibromyalgia.

Authors:  D Munguía-Izquierdo; A Legaz-Arrese
Journal:  Clin Exp Rheumatol       Date:  2007 Nov-Dec       Impact factor: 4.473

8.  The efficacy and safety of milnacipran for treatment of fibromyalgia. a randomized, double-blind, placebo-controlled trial.

Authors:  Philip J Mease; Daniel J Clauw; R Michael Gendreau; Srinivas G Rao; Jay Kranzler; Wei Chen; Robert H Palmer
Journal:  J Rheumatol       Date:  2009-02       Impact factor: 4.666

9.  Minimal clinically important difference in the fibromyalgia impact questionnaire.

Authors:  Robert M Bennett; Andrew G Bushmakin; Joseph C Cappelleri; Gergana Zlateva; Alesia B Sadosky
Journal:  J Rheumatol       Date:  2009-04-15       Impact factor: 4.666

10.  Toward the identification of symptom patterns in people with fibromyalgia.

Authors:  Hilary D Wilson; James P Robinson; Dennis C Turk
Journal:  Arthritis Rheum       Date:  2009-04-15
View more
  12 in total

1.  Neurocognitive complaints and functional status among patients with chronic fatigue syndrome and fibromyalgia.

Authors:  Karen B Schmaling; Karran L Betterton
Journal:  Qual Life Res       Date:  2015-10-15       Impact factor: 4.147

2.  High-Frequency Medical Cannabis Use Is Associated With Worse Pain Among Individuals With Chronic Pain.

Authors:  Kevin F Boehnke; J Ryan Scott; Evangelos Litinas; Suzanne Sisley; David A Williams; Daniel J Clauw
Journal:  J Pain       Date:  2019-09-24       Impact factor: 5.820

3.  Fibrofog in Daily Life: An Examination of Ambulatory Subjective and Objective Cognitive Function in Fibromyalgia.

Authors:  Anna L Kratz; Daniel Whibley; Samsuk Kim; Martin Sliwinski; Daniel Clauw; David A Williams
Journal:  Arthritis Care Res (Hoboken)       Date:  2020-11-09       Impact factor: 4.794

Review 4.  Patient-Reported Outcomes and Fibromyalgia.

Authors:  David A Williams; Anna L Kratz
Journal:  Rheum Dis Clin North Am       Date:  2016-03-17       Impact factor: 2.670

5.  Sensory sensitivity and symptom severity represent unique dimensions of chronic pain: a MAPP Research Network study.

Authors:  Andrew Schrepf; David A Williams; Robert Gallop; Bruce D Naliboff; Neil Basu; Chelsea Kaplan; Daniel E Harper; J Richard Landis; J Quentin Clemens; Eric Strachan; James W Griffith; Niloofar Afari; Afton Hassett; Michel A Pontari; Daniel J Clauw; Steven E Harte
Journal:  Pain       Date:  2018-10       Impact factor: 6.961

6.  The PROMIS FatigueFM Profile: a self-report measure of fatigue for use in fibromyalgia.

Authors:  Anna L Kratz; Stephen Schilling; Jenna Goesling; David A Williams
Journal:  Qual Life Res       Date:  2016-01-28       Impact factor: 4.147

7.  Phenotypic Features of Central Sensitization.

Authors:  David A Williams
Journal:  J Appl Biobehav Res       Date:  2018-06-27

8.  Cost-utility and biological underpinnings of Mindfulness-Based Stress Reduction (MBSR) versus a psychoeducational programme (FibroQoL) for fibromyalgia: a 12-month randomised controlled trial (EUDAIMON study).

Authors:  Albert Feliu-Soler; Xavier Borràs; María T Peñarrubia-María; Antoni Rozadilla-Sacanell; Francesco D'Amico; Rona Moss-Morris; Matthew A Howard; Nicolás Fayed; Carles Soriano-Mas; Marta Puebla-Guedea; Antoni Serrano-Blanco; Adrián Pérez-Aranda; Raffaele Tuccillo; Juan V Luciano
Journal:  BMC Complement Altern Med       Date:  2016-02-27       Impact factor: 3.659

9.  Tobacco Use in Fibromyalgia Is Associated With Cognitive Dysfunction: A Prospective Questionnaire Study.

Authors:  Lin Ge; Ryan S D'Souza; Terry Oh; Ann Vincent; Arya B Mohabbat; Jason Eldrige; Li Jiang; Mary O Whipple; Samantha J McAllister; Zhen Wang; Wenchun Qu; William D Mauck
Journal:  Mayo Clin Proc Innov Qual Outcomes       Date:  2019-02-26

10.  Subjective Cognitive Impairment in 55-65-Year-Old Adults Is Associated with Negative Affective Symptoms, Neuroticism, and Poor Quality of Life.

Authors:  Amy Jenkins; Jeremy J Tree; Ian M Thornton; Andrea Tales
Journal:  J Alzheimers Dis       Date:  2019       Impact factor: 4.472

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.